Halobetasol propionate lotion shows efficacy for Tx of psoriasis

October 10, 2018

(HealthDay)—Halobetasol propionate 0.01 percent lotion (BRYHALI Lotion) appears safe and effective for the treatment of moderate-to-severe plaque psoriasis, according to the results of two phase 3 trials published in the October issue of the Journal of Drugs in Dermatology.

Lawrence J. Green, M.D., from George Washington University in Washington, D.C., and colleagues randomized (2:1) 430 to receive halobetasol propionate Lotion or vehicle once daily for eight weeks, with assessments at two, four, six, and eight weeks of treatment as well as at a four-week post-treatment follow-up visit.

The researchers found that the halobetasol propionate lotion was consistently more effective than the vehicle in achieving treatment success (defined as at least a two-grade improvement from baseline in an Investigator Global Assessment score and "clear" or "almost clear" skin). At eight weeks, 36.5 percent (Study 1) and 38.4 percent (Study 2) of lotion patients achieved versus 8.1 and 12 percent of patients, respectively, receiving vehicle. There was no rebound of symptoms at the four-week post-treatment assessment. A similar number of patients in the lotion and vehicle groups reported (21.5 and 23.9 percent, respectively), and only 1.8 percent of reported adverse events were considered treatment-related.

"If approved, BRYHALI Lotion can provide physicians and their patients with a new option with a longer duration of use," a coauthor said in a statement.

Several authors disclosed financial ties to pharmaceutical companies, including Ortho Dermatologics, which manufactures halobetasol propionate and funded the study.

Explore further: Shower cream, body lotion combo improves atopic dry skin

More information: Abstract/Full Text (subscription or payment may be required)

Related Stories

Shower cream, body lotion combo improves atopic dry skin

May 15, 2018
(HealthDay)—A shower cream and a body lotion with physiological lipids are effective in improving skin hydration in patients with dry skin, according to a study published online May 10 in the Journal of Cosmetic Dermatology.

TYK2 inhibitor clears psoriasis over 12 weeks

October 9, 2018
(HealthDay)—Selective inhibition of TYK2 with the oral agent BMS-986165 at doses of 3 mg daily and higher results in greater clearing of psoriasis versus placebo over 12 weeks, according to a phase 2 study published in ...

Fostamatinib seems effective for immune thrombocytopenia

September 5, 2018
(HealthDay)—Fostamatinib produces clinically meaningful responses in adults with immune thrombocytopenia (ITP), according a study published in the July issue of the American Journal of Hematology.

Secukinumab effective for moderate / severe scalp psoriasis

September 29, 2017
(HealthDay)—Secukinumab is safe and effective as a treatment for patients with extensive moderate-to-severe scalp psoriasis, according to a study published in the October issue of the Journal of the American Academy of ...

Single topical ivermectin head lice treatment very effective

November 2, 2012
(HealthDay)—A single 10-minute, at-home treatment with topical ivermectin lotion eliminates head lice infestations in nearly all patients by the next day, according to a study published in the Nov. 1 issue of the New England ...

ABP 501, adalimumab biosimilar, safe and effective, for psoriasis

August 2, 2017
(HealthDay)—The biosimilar ABP 501 has similar clinical efficacy and safety to adalimumab for the treatment of moderate-to-severe plaque psoriasis, according to a study published online July 28 in the British Journal of ...

Recommended for you

Bug guts shed light on Central America Chagas disease

October 18, 2018
In Central America, Chagas disease, or American trypanosomiasis, is spread by the "kissing bug" Triatoma dimidiata. By collecting DNA from the guts of these bugs, researchers reporting in PLOS Neglected Tropical Diseases ...

Rapid genomic sequencing of Lassa virus in Nigeria enabled real-time response to 2018 outbreak

October 18, 2018
Mounting a collaborative, real-time response to a Lassa fever outbreak in early 2018, doctors and scientists in Nigeria teamed up with researchers at Broad Institute of MIT and Harvard and colleagues to rapidly sequence the ...

Researchers cure drug-resistant infections without antibiotics

October 17, 2018
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria ...

Infectious disease consultation significantly reduces mortality of patients with bloodstream yeast infections

October 17, 2018
In a retrospective cohort study conducted at the University of Alabama at Birmingham Division of Infectious Diseases, patients with candidemia—a yeast infection in the bloodstream—had more positive outcomes as they relate ...

How drug resistant TB evolved and spread globally

October 17, 2018
The most common form of Mycobacterium tuberculosis (TB) originated in Europe and spread to Asia, Africa and the Americas with European explorers and colonialists, reveals a new study led by UCL and the Norwegian Institute ...

Marker may help target treatments for Crohn's patients

October 16, 2018
Crohn's disease (CD), a chronic inflammatory condition of the intestinal tract, has emerged as a global disease, with rates steadily increasing over the last 50 years. Experts have long suspected that CD likely represents ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.